Karanja (Pongamia pinnata)

Karanja (Pongamia pinnata) is an Ayurvedic medicinal plant whose primary bioactive compound, karanjin, is a furanoflavonoid that exhibits anti-inflammatory and antioxidant activity by modulating oxidative stress pathways. Its seed oil and extracts have been used traditionally in Ayurveda for skin disorders, wound healing, and rheumatic conditions, though robust human clinical evidence remains limited.

Origin & History

Karanja derives from the seeds of Pongamia pinnata, a drought-resistant leguminous tree native to India and Southeast Asia, growing 15-20 meters tall. The oil is extracted from seeds containing 10-33% oil through expeller pressing, cold pressing, or solvent extraction, yielding both oil rich in oleic acid (44.5-71.3%) and a nutrient-rich seed cake.

Historical & Cultural Context

In the Indian Ayurvedic system, Karanja (Pongamia pinnata) has been used to treat various ailments for centuries, with seeds and oil employed medicinally. Historical applications also include use as a pesticide, organic fertilizer (N 3.2-3.7%, P 0.22-0.23%, K 0.65-0.68%), and biogas production in traditional South Asian practices.

Health Benefits

• Anti-inflammatory potential based on in vitro studies of karanjin derivatives (PMID: 33257003) - evidence quality: preliminary
• Traditional Ayurvedic use for various ailments - evidence quality: traditional only
• Antioxidant properties attributed to flavonoid content (karanjin 0.57-1.75%, pongamol 0.25-1.27%) - evidence quality: theoretical
• Potential anti-cancer effects from flavonoid compounds - evidence quality: preliminary/theoretical
• No human clinical trials available to substantiate any health benefits

How It Works

Karanjin, a furanoflavonoid present at 0.57–1.75% in seed extracts, inhibits pro-inflammatory mediators including cyclooxygenase (COX) enzymes and suppresses NF-κB signaling, reducing downstream cytokine production such as TNF-α and IL-6. The flavonoid fraction also scavenges reactive oxygen species (ROS) by donating hydrogen atoms to free radicals, measurably reducing lipid peroxidation in vitro. Additionally, pongamol and other chalcone derivatives found in Pongamia pinnata may contribute to antimicrobial activity by disrupting microbial membrane integrity.

Scientific Research

No human clinical trials, RCTs, or meta-analyses for Karanja (Pongamia pinnata) were found in the research. The only PubMed entry (PMID: 33257003) discusses synthesis of karanjin derivatives with anti-inflammatory properties in vitro, noting poor clinical translation due to solubility issues.

Clinical Summary

Current evidence for karanja is almost entirely preclinical; in vitro studies (e.g., PMID: 33257003) demonstrate that karanjin derivatives suppress inflammatory markers in cell culture models, but no large-scale randomized controlled trials in humans have been conducted. Animal studies using Pongamia pinnata seed oil have reported wound-healing acceleration and anti-arthritic effects at oral doses of 200–400 mg/kg, but direct translation to human dosing is uncertain. A small number of traditional-use observational reports support topical karanja oil for skin conditions such as scabies and eczema, yet these lack control groups or quantified outcomes. Overall, the evidence base is preliminary and insufficient to establish efficacy claims in humans.

Nutritional Profile

{"macronutrients": {"protein": "Not significant", "fiber": "Not significant"}, "micronutrients": {"vitamins": "Not significant", "minerals": "Not significant"}, "bioactive_compounds": {"flavonoids": {"karanjin": "0.57-1.75%", "pongamol": "0.25-1.27%"}}, "bioavailability_notes": "Bioactive compounds such as karanjin and pongamol have been identified, but their bioavailability in humans is not well-studied."}

Preparation & Dosage

No clinically studied dosage ranges are available as human trials are absent. Traditional uses do not specify standardized forms, extracts, or dosing. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Turmeric, Boswellia, Ginger, Ashwagandha, Neem

Safety & Interactions

Karanja seed oil and extracts are considered potentially toxic when ingested in large quantities, as the seeds contain bitter resinous compounds including karanjin and pongamol that may cause gastrointestinal irritation, nausea, and vomiting at high doses. Topical application is generally better tolerated, though contact dermatitis has been reported in sensitive individuals. No formal drug interaction studies exist, but given its COX-inhibitory activity, theoretical interactions with NSAIDs or anticoagulants such as warfarin cannot be excluded. Karanja is contraindicated in pregnancy due to traditional reports of uterine-stimulating activity and the absence of safety data; it should also be avoided in children and individuals with liver conditions due to uncharacterized hepatotoxic potential.